CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Docosahexenoic acid (DHA) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00728338
NCT00728338N/ACompleted
CompareCT.gov

Effect of Docosahexenoic Acid (22:6n-3, DHA) Supplementation on Risk Factors for Cardiovascular Disease in Hyperlipidemic Men

USDA, Western Human Nutrition Research Center·interventional·Posted Aug 5, 2008·Updated Aug 8, 2008

In Brief

A clinical study evaluating Docosahexenoic acid (DHA) and Olive oil for Hypertriglyceridemia. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of supplementing diets of hyperlipidemic men with DHA (docosahexenoic acid) on risk factors for cardiovascular disease. We hypothesize that supplementing diets of hyperlipidemic men with DHA will decrease the plasma concentrations of CRP (C-reactive protein), inflammatory cytokines, and soluble adhesion molecules. We further hypothesize that DHA supplementation will decrease serum triglyceride concentrations and increase HDL concentration.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesUnited States
CollaboratorsVA Northern California Health Care System, dsm-firmenich Switzerland AG

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2008
Enrollment StartJun 1, 2003
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 17.9 years ago

Interventions

Docosahexenoic acid (DHA)dietary

The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.

Olive oildietary

7.5 g olive oil/day